Ciltacabtagene Autoleucel – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 14 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[rx] and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients.

Multiple myeloma is a malignancy involving the plasma cells of the bone marrow. It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[rx] and is variable in its presentation – some patients may remain entirely asymptomatic, while others may experience a range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. There have been a number of treatments developed for multiple myeloma (e.g. daratumumab), although none are curative.[rx]

B-cell maturation antigen (BCMA) is a transmembrane glycoprotein member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17) which is used as a biomarker for multiple myeloma.[rx] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development of immunotherapies against multiple myeloma.[rx]

Ciltacabtagene autoleucel (Carvykti, Jannsen Biotech Inc.) is a BCMA-directed genetically modified autologous T-cell immunotherapy.[rx] Patient T-cells are reprogrammed with a transgene encoding a specific chimeric antigen receptor (CAR) which features two BCMA-targeting single-domain antibodies. Re-infusion of these modified T-cells leads to the targeted elimination of malignant plasma cells, on which BCMA is highly expressed.[rx] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[rx]

Mechanism of action

Ciltacabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy in which genetically modified autologous T-cells are reprogrammed to target B-cell maturation antigen (BCMA), a biomarker of multiple myeloma.2 Patient peripheral blood mononuclear cells are obtained via leukapheresis, after which they are enriched for T-cells and genetically modified ex vivo to express a CAR comprising an anti-BCMA targeting domain consisting of two single-domain anti-BCMA antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain.[rx]

The genetically modified CAR T-cells are then expanded, washed, and cryopreserved for shipping back to the patient. When the product is infused back into the patient, the anti-BCMA CAR T-cells are able to recognize and eliminate BCMA-expressing target cells, including malignant plasma cells involved in multiple myeloma.[rx]

Treatment with ciltacabtagene autoleucel comprises a single infusion of a dose range between 0.5-1.0×106 CAR-positive viable T-cells per kilogram of body weight.[rx]

Patients receiving treatment with ciltacabtagene autoleucel are required to undergo monitoring through a Risk Evaluation and Mitigation Strategy (REMS) called the Carvykti REMS.[rx] There are a number of potentially serious adverse reactions related to ciltacabtagene autoleucel therapy which require close monitoring and intervention. Cytokine Release Syndrome (CRS), which may be fatal, may be mitigated with the use of tocilizumab and/or corticosteroids.[rx] Similarly, significant neurologic toxicities (including Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS]) may occur and can be treated with supportive care and/or corticosteroid therapy as required.[rx] Serious hematologic adverse effects – including hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and various recurrent/prolonged cytopenias – have also been observed in patients following treatment with ciltacabtagene autoleucel.[rx]

Indications

  • Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[rx]
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma

Use in Cancer

Ciltacabtagene autoleucel is approved to treat:

  • Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent.

Ciltacabtagene autoleucel is only available as part of a special program called Carvykti REMS (Risk Evaluation and Mitigation StrategiesExit Disclaimer).

Contraindications

  • acute leukemia
  • decreased function of bone marrow
  • anemia
  • decreased blood platelets
  • low levels of white blood cells
  • low levels of a type of white blood cell called neutrophils
  • a decreased number of lymphocytes in the blood
  • a low seizure threshold
  • a type of infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the lung called interstitial pneumonitis
  • a condition where there is a formation of fibrous tissue in the lung called pulmonary chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।" data-rx-term="fibrosis" data-rx-definition="Fibrosis means excess scar-like tissue formation after chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।">fibrosis
  • damage to the liver and infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation
  • liver problems
  • nephrotic syndrome, a type of kidney disorder
  • seizures
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • spread of malignant cancer to the bone marrow

Dosage

Multiple Myeloma

Provided as one bag with a single dose for IV infusion:

  • Recommended dose range: 0.5 to 1.0 × 10(6) CAR-positive viable T cells per kg of body weight
  • Maximum dose of 1×10(8) CAR-positive viable T cells per single infusion
  • Treatment duration: The single IV infusion should be administered within 2.5 hours
  • This drug is for autologous use only. The patient’s identity must match the identifiers on the drug cassette and infusion bag. Do not use if the information on the patient-specific labels does not match.

Precautions

  • US FDA requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides
  • The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for CARVYKTI. It includes a medication guide, a communication plan, elements to assure safe use, and an implementation system. Further information is available at www.carvyktirems.com or 1-844-672-0067 or www.accessdata.fda.gov/scripts/cder/rems/index.cfm

Cytokine Release Syndrome (CRS):

  • CRS, including fatal or life-threatening reactions, has been reported in patients following treatment with this drug.
  • Do not administer to patients with active infection or inflammatory disorders.
  • Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids (see manufacturers prescribing information for further grading and management instructions).

Neurologic Toxicities:

  • Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), may be fatal or life-threatening and has occurred following treatment with this drug, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS.
  • Patients should be monitored for neurologic events after treatment.
  • Provide supportive care and/or corticosteroids as needed (see manufacturers prescribing information for further management instructions).
  • Parkinsonism and Guillain-Barré syndrome and their associated complications resulting in fatal or life-threatening reactions have occurred following treatment with this drug.
  • Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with this drug.
  • HLH/MAS can occur with CRS or neurologic toxicities.
  • Prolonged and/or recurrent cytopenias with bleeding and infection and requirement for stem cell transplantation for hematopoietic recovery occurred following treatment.
  • This drug is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI REMS Program.

Administration advice:

  • See pretreatment and premedication instructions below.
  • This drug is for autologous use only. The patient’s identity must match the patient identifiers on the drug’s cassette and infusion bag. Do not infuse if the information on the patient-specific labels does not match the patient.
  • Do NOT use a infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte-depleting filter.
  • A minimum of two doses of tocilizumab and emergency equipment should be available prior to infusion and during the recovery period.
  • Central venous access may be utilized for the infusion, especially in patients with poor peripheral access.
  • Prime the tubing of the infusion set with normal saline prior to the infusion
  • Once thawed, administer the entire contents of the bag IV within 2.5 hours using infusion sets fitted with an in-line filter.
  • Gently mix the contents of the bag during infusion to disperse cell clumps.
  • Once the entire content of the bag is infused, flush the IV line, including the in-line filter, with normal saline with a volume equal or greater to the total volume of the primary administration set used inclusive of the drip tube, to ensure that all product is delivered.
  • This drug contains human blood cells that are genetically modified with replication incompetent, self-inactivating, lentiviral vector. Follow universal precautions and local biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases.

Pretreatment

  • Administer the lymphodepleting chemotherapy regimen: cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV daily for 3 days.
  • See the prescribing information of cyclophosphamide and fludarabine for further information about this regimen.
  • Administer infusion with this drug 2 to 4 days after the completion of the lymphodepleting chemotherapy regimen.
  • Infusion should be delayed if the patient has:
  • Clinically significant active infection or inflammatory disorders
  • Grade 3 or greater non-hematologic toxicities of cyclophosphamide and fludarabine conditioning, except for Grade 3 nausea, vomiting, diarrhea, or constipation. Delay infusion until resolution of these events to Grade 1 or less.

Premedication

  • Administer pre-infusion medications 30 to 60 minutes prior to this drug:
  • Antipyretics (oral or IV acetaminophen 650 to 1000 mg).
  • Antihistamine (oral or IV diphenhydramine 25 to 50 mg or equivalent).

Reconstitution/preparation techniques:

  • Read the US FDA-approved patient labeling for further receipt, preparation, and administration instructions.

Side Effects

The Most Common

  • diarrhea
  • loss of appetite
  • joint, muscle, or bone pain
  • swelling
  • constipation
  • pyrexia,
  • cytokine release syndrome,
  • hypogammaglobulinemia,
  • musculoskeletal pain, fatigue,
  • infections, diarrhea, nausea,
  • encephalopathy,
  • headache,
  • coagulopathy,
  • low levels of neutrophils,
  • lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells),
  • anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets),
  • hypotension (low blood pressure),
  • the pain of the muscles and bones,
  • high level of liver enzymes,
  • upper respiratory tract infection (nose and throat infection),
  • hypokalemia (low level of potassium),
  • hypocalcemia (low levels of calcium),
  • hypophosphatemia (low levels of phosphate in the blood)
  • tachycardia (rapid heartbeat),
  • encephalopathy (a brain disorder),
  • edema (fluid retention), decreased appetite, chills, fever,
  • tiredness, as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain, and low blood pressure).[rx]

More Common

  • confusion, loss of consciousness, seizures, problems with speech, reading or writing, depression;
  • tingling and numbness of hands and feet , leg and arm weakness, facial numbness; or
  • low blood cell counts–fever, chills, tiredness, flu-like symptoms, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands, and feet, feeling light-headed or short of breath.
  • confusion, cough, trouble breathing, fast or irregular heartbeats, feeling light-headed or very tired;
  • headache, dizziness;
  • problems with speech;
  • low blood cell counts;
  • fever, chills, tiredness, or other signs of infection;
  • decreased appetite, constipation, nausea or diarrhea; or
  • pain in your joints or muscles.

Rare

  • Discouragement
  • feeling sad or empty
  • generalized slowing of mental and physical activity
  • incremental or ratchet-like movement of the muscle
  • lack of appetite
  • loss of balance control
  • loss of interest or pleasure
  • muscle discomfort
  • partial or slight paralysis
  • rigid or stiff muscles
  • seizures
  • shuffling walk
  • slowed movements
  • slurred speech
  • stiffness of the arms and legs
  • tic-like (jerky) movements of the head, face, mouth, and neck
  • trouble concentrating
  • trouble sleeping
  • uncontrolled eye movements

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interacAdd Newtion does not necessarily mean no interactions exist.

  • adalimumab
  • adenovirus vaccine
  • alefacept
  • alemtuzumab
  • anakinra
  • anthrax vaccine adsorbed
  • azathioprine
  • baricitinib
  • bcg
  • bcg vaccine
  • beclomethasone
  • betamethasone
  • bifidobacterium infantis
  • brewer’s yeast
  • budesonide
  • canakinumab
  • candida albicans extract
  • cat’s claw
  • certolizumab
  • chloramphenicol
  • chloramphenicol ophthalmic
  • cholera vaccine
  • cholera vaccine, live
  • ciclesonide
  • cinoxacin
  • ciprofloxacin
  • cladribine
  • clozapine
  • coccidioidin skin test
  • cortisone
  • deferiprone
  • deflazacort
  • delafloxacin
  • dengue vaccine
  • denosumab
  • deucravacitinib
  • dexamethasone
  • dimethyl fumarate
  • diroximel fumarate
  • echinacea
  • efalizumab
  • eflapegrastim
  • enoxacin
  • etanercept
  • fexinidazole
  • filgrastim
  • fingolimod
  • fludrocortisone
  • flunisolide
  • fluticasone
  • ganciclovir
  • gatifloxacin
  • gemifloxacin
  • golimumab
  • grepafloxacin
  • haemophilus b conjugate (hboc) vaccine
  • haemophilus b conjugate (prp-omp) vaccine
  • haemophilus b conjugate (prp-t) vaccine
  • hepatitis a adult vaccine
  • hepatitis a pediatric vaccine
  • hepatitis b adult vaccine
  • hepatitis b pediatric vaccine
  • histoplasmin
  • human papillomavirus vaccine
  • hydrocortisone
  • idelalisib
  • infliximab
  • influenza virus vaccine, h1n1, inactivated
  • influenza virus vaccine, h1n1, live
  • influenza virus vaccine, h5n1
  • influenza virus vaccine, inactivated
  • influenza virus vaccine, live, trivalent
  • japanese enceph vacc sa14-14-2, inactivated
  • japanese encephalitis virus vaccine nakayama
  • lactobacillus acidophilus
  • lactobacillus reuteri
  • lactobacillus rhamnosus
  • lactobacillus rhamnosus gg
  • leflunomide
  • levofloxacin
  • lomefloxacin
  • lyme disease vaccine
  • measles virus vaccine
  • meningococcal conjugate vaccine
  • meningococcal group B vaccine
  • meningococcal polysaccharide vaccine
  • methylprednisolone
  • mixed respiratory vaccine
  • mometasone
  • monomethyl fumarate
  • moxifloxacin
  • mumps skin test antigen
  • mumps virus vaccine
  • nalidixic acid
  • natalizumab
  • niraparib
  • norfloxacil
  • ocrelizumab
  • ofloxacin
  • olaparib
  • omacetaxine
  • ozanimod
  • palifermin
  • pegfilgrastim
  • plague vaccine
  • pneumococcal 13-valent vaccine
  • pneumococcal 15-valent conjugate vaccine
  • pneumococcal 20-valent conjugate vaccine
  • pneumococcal 23-polyvalent vaccine
  • pneumococcal 7-valent vaccine
  • poliovirus vaccine, inactivated
  • poliovirus vaccine, live, trivalent
  • ponesimod
  • prednisolone
  • prednisone
  • rabies vaccine, human diploid cell
  • rabies vaccine, purified chick embryo cell
  • radium 223 dichloride
  • rilonacept
  • roflumilast
  • ropeginterferon alfa-2b
  • rotavirus vaccine
  • rubella virus vaccine
  • saccharomyces boulardii lyo
  • samarium sm 153 lexidronam
  • sargramostim
  • sars-cov-2 (covid-19) ad26 vaccine, recombinant
  • sars-cov-2 (covid-19) chadox1 vaccine, recombinant
  • sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine
  • sars-cov-2 (covid-19) mrna (tozinameran 5y-11y) bivalent booster vaccine
  • sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent booster vaccine
  • sars-cov-2 (covid-19) mrna-1273 (6m-5y bivalent booster) vaccine
  • sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine
  • sars-cov-2 (covid-19) mrna-1273 vaccine
  • sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant
  • sars-cov-2 (covid-19) rs-nanoparticle vaccine, recombinant
  • sars-cov-2 (covid-19)mrna-1273(6y+ bivalent booster) vaccine
  • sars-cov-2 mrna (tozinameran 5y-11y) vaccine
  • sars-cov-2 mrna (tozinameran 6m-4y) vaccine
  • sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine
  • sars-cov-2 mrna (tozinameran) vaccine
  • sars-cov-2 mrna-1273 (6m-5y) vaccine
  • sars-cov-2 mrna-1273 (6y-11y) vaccine
  • sars-cov-2 mrna-1273 (booster only) vaccine
  • sars-cov-2 pres dtm (booster only) vaccine, recombinant
  • siponimod
  • sipuleucel-T
  • skin test antigens, multiple
  • smallpox and monkeypox vaccine
  • smallpox vaccine
  • sodium phosphate p32
  • sparfloxacin
  • staphage lysate (spl)
  • strontium-89 chloride
  • talimogene laherparepvec
  • tbo-filgrastim
  • teriflunomide
  • tetanus toxoid
  • thalidomide
  • tick-borne encephalitis (inactivated) pediatric vaccine
  • tick-borne encephalitis (inactivated) vaccine
  • tofacitinib
  • topotecan
  • triamcinolone
  • trichophyton skin test
  • trovafloxacin
  • tuberculin purified protein derivative
  • typhoid vaccine, inactivated
  • typhoid vaccine, live
  • upadacitinib
  • ustekinumab
  • valganciclovir
  • varicella virus vaccine
  • vitamin e
  • voclosporin
  • yellow fever vaccine
  • zidovudine
  • zinc acetate
  • zinc chloride
  • zinc gluconate
  • zinc sulfate
  • zoster vaccine live
  • zoster vaccine, inactivated

Pregnancy and Lactation

US FDA pregnancy category Not Assigned

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. There is no data on use in pregnant women to know this drug’s risks, including the risk of fetal harm or reproductive effects. Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia and hypogammaglobulinemia. This drug is not recommended for women who are pregnant, or for women of childbearing potential not using contraception.

Lactation

There is no information regarding this drug on its presence in human milk, its effects on a breastfed infant, or its effects on milk production.
-Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition.

How should this medicine be used?

Ciltacabtagene autoleucel comes as a suspension (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a hospital or infusion center. It is usually given over 30 to 60 minutes as a one-time dose. Before you receive your ciltacabtagene autoleucel dose, your doctor or nurse will administer other chemotherapy medications to prepare your body for ciltacabtagene autoleucel.

Before your dose of ciltacabtagene autoleucel injection is to be given, a sample of your white blood cells will be taken at a cell collection center using a procedure called leukapheresis (a process that removes white blood cells from the body). Because this medication is made from your own cells, it must be given only to you. It is important to be on time and to not to miss your scheduled cell collection appointment(s) or to receive your treatment dose. Your healthcare provider will check you daily for at least 10 days after you receive your ciltacabtagene autoleucel dose to monitor you for any side effects. You should also plan to stay near where you received your ciltacabtagene autoleucel treatment for at least 4 weeks after your dose. Your healthcare provider will check to see if your treatment is working and monitor you for any possible side effects. Talk to your doctor about how to prepare for leukapheresis and what to expect during and after the procedure.

What special precautions should I follow?

Before receiving ciltacabtagene autoleucel,

  • tell your doctor and pharmacist if you are allergic to ciltacabtagene autoleucel, any other medications, dimethyl sulfoxide (DMSO), or any of the ingredients in ciltacabtagene autoleucel injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if have or have ever had hepatitis B or C (HBV or HCV; viruses that infect the liver and may cause severe liver damage) or other viruses such as cytomegalovirus (a common virus that usually only causes serious symptoms in people who have weakened immune systems or who are infected at birth) or human immunodeficiency virus (HIV); lung or breathing problems; or kidney, heart, or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You will need to have a pregnancy test before you start ciltacabtagene autoleucel. You or your partner should not become pregnant while you are receiving ciltacabtagene autoleucel. If you become pregnant while receiving ciltacabtagene autoleucel, call your doctor immediately. Ciltacabtagene autoleucel may harm the fetus.
  • you should know that ciltacabtagene autoleucel injection may make you drowsy and cause confusion, weakness, dizziness, seizures, and coordination problems. Do not drive a car or operate machinery for at least 8 weeks after your ciltacabtagene autoleucel dose.
  • do not donate blood, organs, tissues, or cells for transplantation after you receive your ciltacabtagene autoleucel injection.
  • check with your doctor to see if you need to receive any vaccinations. Do not have any vaccinations without talking to your doctor for at least 6 weeks before starting chemotherapy, during your ciltacabtagene autoleucel treatment, and until your doctor tells you that your immune system has recovered.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Ciltacabtagene Autoleucel – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action Ciltacabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy in which genetically modified autologous T-cells are reprogrammed to target B-cell maturation antigen (BCMA), a biomarker of multiple myeloma.2 Patient peripheral blood mononuclear cells are obtained via leukapheresis, after which they are enriched for T-cells and genetically modified ex vivo to express a CAR comprising an anti-BCMA targeting domain consisting of two single-domain anti-BCMA antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain.[rx] The genetically modified CAR T-cells are then expanded, washed, and cryopreserved for shipping back to the patient. When the product is infused back into the patient, the anti-BCMA CAR T-cells are able to recognize and eliminate BCMA-expressing target cells, including malignant plasma cells involved in multiple myeloma.[rx] Treatment with ciltacabtagene autoleucel comprises a single infusion of a dose range between 0.5-1.0x106 CAR-positive viable T-cells per kilogram of body weight.[rx] Patients receiving treatment with ciltacabtagene autoleucel are required to undergo monitoring through a Risk Evaluation and Mitigation Strategy (REMS) called the Carvykti REMS.[rx] There are a number of potentially serious adverse reactions related to ciltacabtagene autoleucel therapy which require close monitoring and intervention. Cytokine Release Syndrome (CRS), which may be fatal, may be mitigated with the use of tocilizumab and/or corticosteroids.[rx] Similarly, significant neurologic toxicities (including Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS]) may occur and can be treated with supportive care and/or corticosteroid therapy as required.[rx] Serious hematologic adverse effects - including hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and various recurrent/prolonged cytopenias - have also been observed in patients following treatment with ciltacabtagene autoleucel.[rx] Indications Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[rx] Refractory Multiple Myeloma Relapsed Multiple Myeloma Use in Cancer Ciltacabtagene autoleucel is approved to treat: Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent. Ciltacabtagene autoleucel is only available as part of a special program called Carvykti REMS (Risk Evaluation and Mitigation StrategiesExit Disclaimer). Contraindications acute leukemia decreased function of bone marrow anemia decreased blood platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils a decreased number of lymphocytes in the blood a low seizure threshold a type of inflammation of the lung called interstitial pneumonitis a condition where there is a formation of fibrous tissue in the lung called pulmonary fibrosis damage to the liver and inflammation liver problems nephrotic syndrome, a type of kidney disorder seizures pregnancy a patient who is producing milk and breastfeeding spread of malignant cancer to the bone marrow Dosage Multiple Myeloma Provided as one bag with a single dose for IV infusion: Recommended dose range: 0.5 to 1.0 × 10(6) CAR-positive viable T cells per kg of body weight Maximum dose of 1×10(8) CAR-positive viable T cells per single infusion Treatment duration: The single IV infusion should be administered within 2.5 hours This drug is for autologous use only. The patient's identity must match the identifiers on the drug cassette and infusion bag. Do not use if the information on the patient-specific labels does not match. Precautions US FDA requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for CARVYKTI. It includes a medication guide, a communication plan, elements to assure safe use, and an implementation system. Further information is available at www.carvyktirems.com or 1-844-672-0067 or www.accessdata.fda.gov/scripts/cder/rems/index.cfm Cytokine Release Syndrome (CRS): CRS, including fatal or life-threatening reactions, has been reported in patients following treatment with this drug. Do not administer to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids (see manufacturers prescribing information for further grading and management instructions). Neurologic Toxicities: Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), may be fatal or life-threatening and has occurred following treatment with this drug, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Patients should be monitored for neurologic events after treatment. Provide supportive care and/or corticosteroids as needed (see manufacturers prescribing information for further management instructions). Parkinsonism and Guillain-Barré syndrome and their associated complications resulting in fatal or life-threatening reactions have occurred following treatment with this drug. Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with this drug. HLH/MAS can occur with CRS or neurologic toxicities. Prolonged and/or recurrent cytopenias with bleeding and infection and requirement for stem cell transplantation for hematopoietic recovery occurred following treatment. This drug is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CARVYKTI REMS Program. Administration advice: See pretreatment and premedication instructions below. This drug is for autologous use only. The patient's identity must match the patient identifiers on the drug's cassette and infusion bag. Do not infuse if the information on the patient-specific labels does not match the patient. Do NOT use a leukocyte-depleting filter. A minimum of two doses of tocilizumab and emergency equipment should be available prior to infusion and during the recovery period. Central venous access may be utilized for the infusion, especially in patients with poor peripheral access. Prime the tubing of the infusion set with normal saline prior to the infusion Once thawed, administer the entire contents of the bag IV within 2.5 hours using infusion sets fitted with an in-line filter. Gently mix the contents of the bag during infusion to disperse cell clumps. Once the entire content of the bag is infused, flush the IV line, including the in-line filter, with normal saline with a volume equal or greater to the total volume of the primary administration set used inclusive of the drip tube, to ensure that all product is delivered. This drug contains human blood cells that are genetically modified with replication incompetent, self-inactivating, lentiviral vector. Follow universal precautions and local biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases. Pretreatment Administer the lymphodepleting chemotherapy regimen: cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV daily for 3 days. See the prescribing information of cyclophosphamide and fludarabine for further information about this regimen. Administer infusion with this drug 2 to 4 days after the completion of the lymphodepleting chemotherapy regimen. Infusion should be delayed if the patient has: Clinically significant active infection or inflammatory disorders Grade 3 or greater non-hematologic toxicities of cyclophosphamide and fludarabine conditioning, except for Grade 3 nausea, vomiting, diarrhea, or constipation. Delay infusion until resolution of these events to Grade 1 or less. Premedication Administer pre-infusion medications 30 to 60 minutes prior to this drug: Antipyretics (oral or IV acetaminophen 650 to 1000 mg). Antihistamine (oral or IV diphenhydramine 25 to 50 mg or equivalent). Reconstitution/preparation techniques: Read the US FDA-approved patient labeling for further receipt, preparation, and administration instructions. Side Effects The Most Common diarrhea loss of appetite joint, muscle, or bone pain swelling constipation pyrexia, cytokine release syndrome, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections, diarrhea, nausea, encephalopathy, headache, coagulopathy, low levels of neutrophils, lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells), anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), hypotension (low blood pressure), the pain of the muscles and bones, high level of liver enzymes, upper respiratory tract infection (nose and throat infection), hypokalemia (low level of potassium), hypocalcemia (low levels of calcium), hypophosphatemia (low levels of phosphate in the blood) tachycardia (rapid heartbeat), encephalopathy (a brain disorder), edema (fluid retention), decreased appetite, chills, fever, tiredness, as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain, and low blood pressure).[rx] More Common confusion, loss of consciousness, seizures, problems with speech, reading or writing, depression; tingling and numbness of hands and feet , leg and arm weakness, facial numbness; or low blood cell counts--fever, chills, tiredness, flu-like symptoms, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands, and feet, feeling light-headed or short of breath. confusion, cough, trouble breathing, fast or irregular heartbeats, feeling light-headed or very tired; headache, dizziness; problems with speech; low blood cell counts; fever, chills, tiredness, or other signs of infection; decreased appetite, constipation, nausea or diarrhea; or pain in your joints or muscles. Rare Discouragement feeling sad or empty generalized slowing of mental and physical activity incremental or ratchet-like movement of the muscle lack of appetite loss of balance control loss of interest or pleasure muscle discomfort partial or slight paralysis rigid or stiff muscles seizures shuffling walk slowed movements slurred speech stiffness of the arms and legs tic-like (jerky) movements of the head, face, mouth, and neck trouble concentrating trouble sleeping uncontrolled eye movements Drug Interactions This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interacAdd Newtion does not necessarily mean no interactions exist. adalimumab adenovirus vaccine alefacept alemtuzumab anakinra anthrax vaccine adsorbed azathioprine baricitinib bcg bcg vaccine beclomethasone betamethasone bifidobacterium infantis brewer's yeast budesonide canakinumab candida albicans extract cat's claw certolizumab chloramphenicol chloramphenicol ophthalmic cholera vaccine cholera vaccine, live ciclesonide cinoxacin ciprofloxacin cladribine clozapine coccidioidin skin test cortisone deferiprone deflazacort delafloxacin dengue vaccine denosumab deucravacitinib dexamethasone dimethyl fumarate diroximel fumarate echinacea efalizumab eflapegrastim enoxacin etanercept fexinidazole filgrastim fingolimod fludrocortisone flunisolide fluticasone ganciclovir gatifloxacin gemifloxacin golimumab grepafloxacin haemophilus b conjugate (hboc) vaccine haemophilus b conjugate (prp-omp) vaccine haemophilus b conjugate (prp-t) vaccine hepatitis a adult vaccine hepatitis a pediatric vaccine hepatitis b adult vaccine hepatitis b pediatric vaccine histoplasmin human papillomavirus vaccine hydrocortisone idelalisib infliximab influenza virus vaccine, h1n1, inactivated influenza virus vaccine, h1n1, live influenza virus vaccine, h5n1 influenza virus vaccine, inactivated influenza virus vaccine, live, trivalent japanese enceph vacc sa14-14-2, inactivated japanese encephalitis virus vaccine nakayama lactobacillus acidophilus lactobacillus reuteri lactobacillus rhamnosus lactobacillus rhamnosus gg leflunomide levofloxacin lomefloxacin lyme disease vaccine measles virus vaccine meningococcal conjugate vaccine meningococcal group B vaccine meningococcal polysaccharide vaccine methylprednisolone mixed respiratory vaccine mometasone monomethyl fumarate moxifloxacin mumps skin test antigen mumps virus vaccine nalidixic acid natalizumab niraparib norfloxacil ocrelizumab ofloxacin olaparib omacetaxine ozanimod palifermin pegfilgrastim plague vaccine pneumococcal 13-valent vaccine pneumococcal 15-valent conjugate vaccine pneumococcal 20-valent conjugate vaccine pneumococcal 23-polyvalent vaccine pneumococcal 7-valent vaccine poliovirus vaccine, inactivated poliovirus vaccine, live, trivalent ponesimod prednisolone prednisone rabies vaccine, human diploid cell rabies vaccine, purified chick embryo cell radium 223 dichloride rilonacept roflumilast ropeginterferon alfa-2b rotavirus vaccine rubella virus vaccine saccharomyces boulardii lyo samarium sm 153 lexidronam sargramostim sars-cov-2 (covid-19) ad26 vaccine, recombinant sars-cov-2 (covid-19) chadox1 vaccine, recombinant sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine sars-cov-2 (covid-19) mrna (tozinameran 5y-11y) bivalent booster vaccine sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent booster vaccine sars-cov-2 (covid-19) mrna-1273 (6m-5y bivalent booster) vaccine sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine sars-cov-2 (covid-19) mrna-1273 vaccine sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant sars-cov-2 (covid-19) rs-nanoparticle vaccine, recombinant sars-cov-2 (covid-19)mrna-1273(6y+ bivalent booster) vaccine sars-cov-2 mrna (tozinameran 5y-11y) vaccine sars-cov-2 mrna (tozinameran 6m-4y) vaccine sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine sars-cov-2 mrna (tozinameran) vaccine sars-cov-2 mrna-1273 (6m-5y) vaccine sars-cov-2 mrna-1273 (6y-11y) vaccine sars-cov-2 mrna-1273 (booster only) vaccine sars-cov-2 pres dtm (booster only) vaccine, recombinant siponimod sipuleucel-T skin test antigens, multiple smallpox and monkeypox vaccine smallpox vaccine sodium phosphate p32 sparfloxacin staphage lysate (spl) strontium-89 chloride talimogene laherparepvec tbo-filgrastim teriflunomide tetanus toxoid thalidomide tick-borne encephalitis (inactivated) pediatric vaccine tick-borne encephalitis (inactivated) vaccine tofacitinib topotecan triamcinolone trichophyton skin test trovafloxacin tuberculin purified protein derivative typhoid vaccine, inactivated typhoid vaccine, live upadacitinib ustekinumab valganciclovir varicella virus vaccine vitamin e voclosporin yellow fever vaccine zidovudine zinc acetate zinc chloride zinc gluconate zinc sulfate zoster vaccine live zoster vaccine, inactivated Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. There is no data on use in pregnant women to know this drug's risks, including the risk of fetal harm or reproductive effects. Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia and hypogammaglobulinemia. This drug is not recommended for women who are pregnant, or for women of childbearing potential not using contraception. Lactation There is no information regarding this drug on its presence in human milk, its effects on a breastfed infant, or its effects on milk production. -Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition. How should this medicine be used?

Ciltacabtagene autoleucel comes as a suspension (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a hospital or infusion center. It is usually given over 30 to 60 minutes as a one-time dose. Before you receive your ciltacabtagene autoleucel dose, your doctor or nurse will administer other chemotherapy medications to prepare your body for ciltacabtagene autoleucel. Before your dose of ciltacabtagene autoleucel injection is to be given, a sample of your white blood cells will…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)